Claims for Patent: 9,693,989
✉ Email this page to a colleague
Summary for Patent: 9,693,989
| Title: | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| Abstract: | This invention provides compounds of Formula I ##STR00001## wherein B, G, A, E, R.sup.1, R.sup.2, R.sup.3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals. |
| Inventor(s): | Lyssikatos; Joseph P. (Piedmont, CA), Hicks; Julie Marie (Erie, CO), Marmsater; Fredrik P. (Boulder, CO), Zhao; Qian (Superior, CO) |
| Assignee: | Array Biopharma, Inc. (Boulder, CO) |
| Application Number: | 14/034,361 |
| Patent Claims: |
1. A pharmaceutical composition comprising a compound having the Formula: ##STR00354## or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable
diluent or carrier.
2. The pharmaceutical composition of claim 1, wherein the compound has the Formula: ##STR00355## or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical composition of claim 1, wherein the compound has the Formula: ##STR00356## or a pharmaceutically acceptable salt thereof. 4. The composition of claim 1, wherein an anti-tumor agent is administered in combination. 5. The composition of claim 4, wherein the anti-tumor agent is an anti-metabolite. 6. The composition of claim 5, wherein the anti-metabolite is 5-fluorouracil. 7. The composition of claim 4, wherein the anti-tumor agent is an antimitotic agent. 8. The composition of claim 7, wherein the antimitotic agent is selected from the group consisting of taxol and taxotere. 9. The composition of claim 4, wherein the anti-tumor agent is an inhibitor of growth factor function. 10. The composition of claim 9, wherein the inhibitor of growth factor function is trastuzumab. 11. The composition of claim 4, wherein the anti-tumor agent is an antiangiogenic agent. 12. The composition of claim 11, wherein the antiangiogenic agent is bevacizumab. 13. A method of treating a cancer that over-expresses HER2 in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound having the Formula: ##STR00357## or a pharmaceutically acceptable salt thereof; wherein the cancer is breast cancer. 14. The method of claim 13, wherein the compound has the Formula: ##STR00358## or a pharmaceutically acceptable salt thereof. 15. The method of claim 13, wherein the compound has the Formula: ##STR00359## or a pharmaceutically acceptable salt thereof. 16. The method of claim 13, wherein the compound has the Formula: ##STR00360## 17. The method of claim 13, wherein the compound has the Formula: ##STR00361## 18. The method of claim 13, wherein an anti-tumor agent is administered in combination. 19. The method of claim 18, wherein the anti-tumor agent is an anti-metabolite. 20. The method of claim 19, wherein the anti-metabolite is 5-fluorouracil. 21. The method of claim 18, wherein the anti-tumor agent is an antimitotic agent. 22. The method of claim 21, wherein the antimitotic agent is selected from the group consisting of taxol and taxotere. 23. The method of claim 18, wherein the anti-tumor agent is an inhibitor of growth factor function. 24. The method of claim 23, wherein the inhibitor of growth factor function is trastuzumab. 25. The method of claim 18, wherein the anti-tumor agent is an antiangiogenic agent. 26. The method of claim 25, wherein the antiangiogenic agent is bevacizumab. 27. The pharmaceutical composition of claim 1, wherein the compound has the Formula: ##STR00362## 28. The pharmaceutical composition of claim 1, wherein the compound has the Formula: ##STR00363## |
